Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate ...
If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results